ANDOVER, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the closing of its initial public offering of 6,543,500 shares of its common stock at an initial public offering price of $16.00 per share, including 853,500 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering were approximately $104.7 million, before deducting underwriting discounts and commissions and estimated offering expenses. The shares commenced trading on The Nasdaq Global Market on May 2, 2019 under the ticker symbol “TMDX.” All of the shares were sold by TransMedics.
Morgan Stanley and J.P. Morgan acted as joint lead book-running managers for the offering. Cowen and Canaccord Genuity acted as co-managers for the offering.
A registration statement relating to these securities was filed with the Securities and Exchange Commission and became effective on May 1, 2019. The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or J.P. Morgan Securities LLC, c/o J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone, at (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About TransMedics Group, Inc.
TransMedics is the world’s leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation, and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.
Greg Chodaczek or Lynn Lewis